• Biocon
• 08 Nov, 2020

Biocon on Saturday said its subsidiary Biocon Biologics has approved a Rs 1,125 crore investment from Goldman Sachs. This capital injection by Goldman Sachs will enable Biocon Biologics to make prudent investments in R&D, high-quality manufacturing, as well as, establish a global commercial footprint. The board of Biocon Biologics has approved a Rs 1,125 crore (USD 150 million) capital injection from Goldman Sachs, Biocon said in a statement.
Read more...